Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.21
INVA's Cash-to-Debt is ranked lower than
94% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. INVA: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
INVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.4 Max: N/A
Current: 0.21
Equity-to-Asset -0.80
INVA's Equity-to-Asset is ranked lower than
97% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INVA: -0.80 )
Ranked among companies with meaningful Equity-to-Asset only.
INVA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.04  Med: -0.21 Max: 0.67
Current: -0.8
-1.04
0.67
Interest Coverage 2.79
INVA's Interest Coverage is ranked lower than
95% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INVA: 2.79 )
Ranked among companies with meaningful Interest Coverage only.
INVA' s Interest Coverage Range Over the Past 10 Years
Min: 0.61  Med: 1.35 Max: 2.08
Current: 2.79
0.61
2.08
Piotroski F-Score: 6
Altman Z-Score: -2.45
Beneish M-Score: -1.71
WACC vs ROIC
16.08%
67.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 81.12
INVA's Operating Margin % is ranked higher than
99% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. INVA: 81.12 )
Ranked among companies with meaningful Operating Margin % only.
INVA' s Operating Margin % Range Over the Past 10 Years
Min: -766.13  Med: -402.95 Max: 81.6
Current: 81.12
-766.13
81.6
Net Margin % 52.56
INVA's Net Margin % is ranked higher than
97% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. INVA: 52.56 )
Ranked among companies with meaningful Net Margin % only.
INVA' s Net Margin % Range Over the Past 10 Years
Min: -3766.57  Med: -377.71 Max: 44.57
Current: 52.56
-3766.57
44.57
ROA % 24.45
INVA's ROA % is ranked higher than
96% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. INVA: 24.45 )
Ranked among companies with meaningful ROA % only.
INVA' s ROA % Range Over the Past 10 Years
Min: -75.4  Med: -32.62 Max: 15.11
Current: 24.45
-75.4
15.11
ROC (Joel Greenblatt) % 424.36
INVA's ROC (Joel Greenblatt) % is ranked higher than
97% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. INVA: 424.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1062.05  Med: -536.06 Max: 468.83
Current: 424.36
-1062.05
468.83
3-Year Revenue Growth Rate 191.00
INVA's 3-Year Revenue Growth Rate is ranked higher than
98% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. INVA: 191.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.6 Max: 191
Current: 191
0
191
GuruFocus has detected 3 Warning Signs with Innoviva Inc $INVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INVA's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

INVA Guru Trades in Q3 2016

Joel Greenblatt 94,392 sh (+42.18%)
Paul Tudor Jones 106,236 sh (+29.92%)
Steven Cohen 613,575 sh (+7.44%)
First Eagle Investment 3,584,891 sh (+6.83%)
Seth Klarman 14,931,483 sh (-15.21%)
» More
Q4 2016

INVA Guru Trades in Q4 2016

Seth Klarman 14,931,483 sh (unchged)
Steven Cohen Sold Out
First Eagle Investment 3,431,275 sh (-4.29%)
Joel Greenblatt 85,288 sh (-9.64%)
Paul Tudor Jones 37,531 sh (-64.67%)
» More
Q1 2017

INVA Guru Trades in Q1 2017

Steven Cohen 712,400 sh (New)
Jim Simons 42,920 sh (New)
Paul Tudor Jones 87,754 sh (+133.82%)
Joel Greenblatt 82,000 sh (-3.86%)
First Eagle Investment 3,126,898 sh (-8.87%)
Seth Klarman 11,573,663 sh (-22.49%)
» More
Q2 2017

INVA Guru Trades in Q2 2017

Michael Price 52,500 sh (New)
Joel Greenblatt 571,223 sh (+596.61%)
Steven Cohen 1,335,500 sh (+87.46%)
Jim Simons Sold Out
Seth Klarman Sold Out
First Eagle Investment 2,678,043 sh (-14.35%)
Paul Tudor Jones 37,369 sh (-57.42%)
» More
» Details

Insider Trades

Latest Guru Trades with INVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2017-06-30 Reduce -14.35%0.02%$11.44 - $14.42 $ 12.28-2%2,678,043
Joel Greenblatt 2017-06-30 Add 596.61%0.09%$11.44 - $14.42 $ 12.28-2%571,223
Michael Price 2017-06-30 New Buy0.09%$11.44 - $14.42 $ 12.28-2%52,500
Seth Klarman 2017-06-30 Sold Out 1.9%$11.44 - $14.42 $ 12.28-2%0
Seth Klarman 2017-04-30 Reduce -91.27%1.48%Premium Member Access $11.79 $ 12.284%1,010,624
Seth Klarman 2017-03-31 Reduce -22.49%0.47%$10.43 - $13.83 $ 12.284%11,573,663
First Eagle Investment 2017-03-31 Reduce -8.87%0.01%$10.43 - $13.83 $ 12.284%3,126,898
Joel Greenblatt 2017-03-31 Reduce -3.86%$10.43 - $13.83 $ 12.284%82,000
First Eagle Investment 2016-12-31 Reduce -4.29%$9.37 - $11.2 $ 12.2817%3,431,275
Joel Greenblatt 2016-12-31 Reduce -9.64%$9.37 - $11.2 $ 12.2817%85,288
Seth Klarman 2016-09-30 Reduce -15.21%0.38%$10.84 - $13.04 $ 12.285%14,931,483
First Eagle Investment 2016-09-30 Add 6.83%0.01%$10.84 - $13.04 $ 12.285%3,584,891
Joel Greenblatt 2016-09-30 Add 42.18%$10.84 - $13.04 $ 12.285%94,392
Seth Klarman 2016-08-31 Reduce -1.36%0.04%Premium Member Access $11.09 $ 12.2811%17,371,043
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:XLRN, NYSE:EBS, NAS:ARRY, NAS:GBT, NAS:LXRX, NAS:MYOK, NAS:CORT, NAS:ESPR, NAS:OMER, NAS:HALO, NAS:XNCR, NYSE:CBM, NAS:ACOR, NAS:DERM, NAS:AIMT, NAS:RGEN, NAS:AKCA, NAS:AMRI, NAS:BPMC, NAS:EDIT » details
Traded in other countries:HVE.Germany,
Headquarter Location:USA
Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines.

Theravance develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. The firm has gained approval for lead drug Vibativ for skin infections, but awaits a decision on usage for hospital-acquired pneumonia. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. The firm collaborates with and receives funding from GlaxoSmithKline on this venture.

Ratios

vs
industry
vs
history
PE Ratio 15.35
INVA's PE Ratio is ranked higher than
68% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. INVA: 15.35 )
Ranked among companies with meaningful PE Ratio only.
INVA' s PE Ratio Range Over the Past 10 Years
Min: 14.96  Med: 21.73 Max: 75.71
Current: 15.35
14.96
75.71
PE Ratio without NRI 15.35
INVA's PE Ratio without NRI is ranked higher than
69% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. INVA: 15.35 )
Ranked among companies with meaningful PE Ratio without NRI only.
INVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.96  Med: 21.73 Max: 75.71
Current: 15.35
14.96
75.71
Price-to-Owner-Earnings 19.74
INVA's Price-to-Owner-Earnings is ranked higher than
63% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. INVA: 19.74 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
INVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 19.24  Med: 37.44 Max: 321.75
Current: 19.74
19.24
321.75
PS Ratio 8.96
INVA's PS Ratio is ranked higher than
53% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. INVA: 8.96 )
Ranked among companies with meaningful PS Ratio only.
INVA' s PS Ratio Range Over the Past 10 Years
Min: 8.73  Med: 45.44 Max: 1600
Current: 8.96
8.73
1600
Price-to-Free-Cash-Flow 17.13
INVA's Price-to-Free-Cash-Flow is ranked higher than
63% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. INVA: 17.13 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 16.69  Med: 28.19 Max: 139.55
Current: 17.13
16.69
139.55
Price-to-Operating-Cash-Flow 17.13
INVA's Price-to-Operating-Cash-Flow is ranked higher than
59% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. INVA: 17.13 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 16.69  Med: 28.19 Max: 139.55
Current: 17.13
16.69
139.55
EV-to-EBIT 12.96
INVA's EV-to-EBIT is ranked higher than
63% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. INVA: 12.96 )
Ranked among companies with meaningful EV-to-EBIT only.
INVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -813.9  Med: -9.8 Max: 193.7
Current: 12.96
-813.9
193.7
EV-to-EBITDA 11.81
INVA's EV-to-EBITDA is ranked higher than
60% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. INVA: 11.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
INVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -387.5  Med: -9.4 Max: 360.3
Current: 11.81
-387.5
360.3
Current Ratio 7.31
INVA's Current Ratio is ranked higher than
81% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. INVA: 7.31 )
Ranked among companies with meaningful Current Ratio only.
INVA' s Current Ratio Range Over the Past 10 Years
Min: 2.41  Med: 6.62 Max: 23.9
Current: 7.31
2.41
23.9
Quick Ratio 7.31
INVA's Quick Ratio is ranked higher than
81% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. INVA: 7.31 )
Ranked among companies with meaningful Quick Ratio only.
INVA' s Quick Ratio Range Over the Past 10 Years
Min: 2.41  Med: 6.62 Max: 23.9
Current: 7.31
2.41
23.9
Days Sales Outstanding 128.17
INVA's Days Sales Outstanding is ranked lower than
72% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. INVA: 128.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
INVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.92  Med: 12.39 Max: 456.63
Current: 128.17
2.92
456.63

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 8.23
INVA's 5-Year Yield-on-Cost % is ranked higher than
89% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. INVA: 8.23 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
INVA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.19  Med: 4.24 Max: 13.02
Current: 8.23
1.19
13.02
3-Year Average Share Buyback Ratio 0.90
INVA's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. INVA: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.4  Med: -10.8 Max: 0.9
Current: 0.9
-140.4
0.9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.20
INVA's Price-to-Median-PS-Value is ranked higher than
90% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. INVA: 0.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.2 Max: 34.63
Current: 0.2
0.21
34.63
Earnings Yield (Greenblatt) % 7.72
INVA's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. INVA: 7.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -46.4  Med: -4.6 Max: 7.3
Current: 7.72
-46.4
7.3

More Statistics

Revenue (TTM) (Mil) $175.98
EPS (TTM) $ 0.80
Beta3.11
Short Percentage of Float46.88%
52-Week Range $8.67 - 14.55
Shares Outstanding (Mil)109.36

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 1.31
EPS without NRI ($) 1.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for INVA

Headlines

Articles On GuruFocus.com
Seth Klarman Backs Out of Innoviva Days After Activist Stakeholder Defeated May 10 2017 
Sarissa Asks Innoviva Directors To Explain Continued Director Over-Compensation Despite Promises To Apr 26 2017 
Overwhelming Majority Of Non-GSK Shareholders Support Sarissa Capital And Not Innoviva Board And Man Apr 21 2017 
Innoviva Reneges On Accepted Deal With Sarissa Capital Apr 19 2017 
Sarissa Capital States: Innoviva Already Appears To Renege On Cost Cuts; Innoviva Thinks Its Bad Cor Apr 17 2017 
Sarissa Urges Shareholders To See Through Innoviva's Last Minute Flip-Flop On Cost Cuts; Notes Consp Apr 17 2017 
Sarissa Capital Urges Shareholders Of Innoviva, Inc.: Follow The Recommendations Of ISS, Glass Lewis Apr 13 2017 
Sarissa Capital Files Presentation In Proxy Contest With Innoviva Apr 12 2017 
Egan-Jones Supports All Three Sarissa Capital Nominees For Innoviva Board Apr 12 2017 
Sarissa Capital Is Concerned That Innoviva Will Waste Shareholder Money On Imprudent Acquisitions Apr 11 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Innoviva Inc. Aug 16 2017
Edited Transcript of INVA earnings conference call or presentation 26-Jul-17 9:00pm GMT Aug 12 2017
Innoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : August 9, 2017 Aug 09 2017
Innoviva, Inc. Announces Closing of $175 Million Offering of 2.50% Convertible Senior Notes and... Aug 07 2017
Illumina (ILMN) Catches Eye: Stock Soars 14.8% Aug 03 2017
Innoviva, Inc. Prices Offering of $175 Million of 2.50% Convertible Senior Notes Aug 01 2017
Innoviva, Inc. -- Moody's assigns B3 CFR to Innoviva; stable outlook Aug 01 2017
Innoviva Announces Proposed Offering of $175 Million of Convertible Senior Notes Jul 31 2017
ETFs with exposure to Innoviva, Inc. : July 31, 2017 Jul 31 2017
Innoviva beats 2Q profit forecasts Jul 26 2017
Innoviva Reports Strong Second Quarter 2017 Financial Results Jul 26 2017
Investor Network: Innoviva, Inc. to Host Earnings Call Jul 26 2017
Corporate News Blog - GlaxoSmithKline and Innoviva Submits EU Filing for Extended Use of Relvar... Jul 25 2017
GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an... Jul 21 2017
Innoviva to Report First Quarter Financial Results on July 26 at 5:00 p.m. EDT Jul 19 2017
ETFs with exposure to Innoviva, Inc. : June 20, 2017 Jun 20 2017
Innoviva, Inc. :INVA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 Jun 19 2017
Can This Biotech Stock With 645% EPS Growth Launch New Breakout? Jun 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}